Seattle, WA -- (SBWIRE) -- 03/22/2017 -- The report "Influenza Diagnostics Market Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021", report provides a detailed overview of the major drivers, restraints, opportunities, and threat impacting the influenza diagnostics market along with the estimates and forecasts of the revenue and market share analysis.

Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=222985562

Browse 91 market data tables and 33 figures spread through 127 pages and in-depth TOC on "Influenza Diagnostics Market Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021"

http://www.marketsandmarkets.com/Market-Reports/influenza-diagnostic-market-222985562.html

Early buyers will receive 10% customization on reports.

The global influenza diagnostics market is expected to reach USD 767.4 Million by 2021 from USD 508.0 Million in 2016, at a CAGR of 8.6% from 2016 to 2021. The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza are the major factors that are expected to drive the growth of this market in the coming years. Also, advancements in technologies such as PCR and proteomics and significant growth prospects in developing countries are expected to offer growth opportunities for players in the influenza diagnostics market.

The influenza diagnostics market is segmented on the basis of test type, end user, and region. On the basis of test type, the market is segmented into traditional diagnostic tests and molecular diagnostic tests. The traditional diagnostic tests segment is further divided into rapid influenza detection tests (RIDT), viral culture, direct fluorescent antibody (DFA) tests, and serological assays. The molecular diagnostic tests segment is divided into RT-PCR, nucleic acid sequence-based amplification (NASBA) tests, loop-mediated isothermal amplification-based assays (LAMP), simple amplification-based assays (SAMBA), and other tests (microarray-based approaches and nucleic acid sequencing approaches). Among these, the traditional diagnostic tests segment is expected to account for the largest share of the global influenza diagnostics market in 2016.

On the basis of end user, the market is segmented into hospitals/clinical laboratories, reference laboratories, and other end users (point-of-care testing, local public health laboratories, home health agencies, and nursing homes). The hospitals/clinical laboratories segment is expected to account for the largest share of the market in 2016. The large share of this segment can be attributed to the fact that most influenza disease diagnostic tests are carried out in hospitals and clinical laboratories, as these tests are highly complex in nature and require the use of specialized instruments.

On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and RoW. The European market is expected to account for the largest share of the global influenza diagnostics market in 2016. The large share of this segment is due to the increased prevalence of influenza disease and technological advancements in this region.

The prominent players in the influenza diagnostics market are Thermo Fisher Scientific (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Quidel Corporation (U.S.), Becton, Dickinson and Company (U.S.), DiaSorin (Italy), SA Scientific (U.S.), and Luminex Corporation (U.S.).

About MarketsandMarkets
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. For more information, please visit www.marketsandmarkets.com